The expression of HDAC10 is inhibited in human renal cell carcinoma (RCC) cells, suggesting that HDAC10 is an independent predictor of the prognosis of RCC, and activating HDAC10 expression may be a new therapeutic strategy for advanced RCC 26. This evidence concerns the gene HDAC10 and renal cell carcinoma.